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Abstract
Background: Small-cell lung carcinoma (SCLC) is an aggressive malignancy characterised by an early relapse, a
tendency towards drug resistance, and a high incidence of metastasis. SCLC cells are of neuroendocrine origin and
express high levels of somatostatin receptors; therefore, future treatment might involve targeting tumours with
radiolabelled somatostatin analogues. This therapy induces abundant necrotic patches that contain exposed
keratins; thus, keratin 8, which is one of the most abundant cytoskeletal proteins may represent an interesting
secondary target for SCLC. This study aimed to investigate the effects of
177Lu-DOTA-Tyr
3-octerotate and the
binding of the monoclonal anti-keratin 8 antibody, TS1, in vitro in treated SCLC- and midgut-xenografted mouse
models.
Methods: NCI-H69- and GOT1-xenotransplanted mice were treated with three doses of 30 MBq
177Lu-DOTA-Tyr
3-
octreotate administered 24 h apart. Mice xenotransplanted with NCI-H69 were sacrificed 1, 5, 12, 20 and 150 days
post-injection or when the tumour had regrown to its original size. GOT1-xenotransplanted mice were sacrificed 3
days post-injection. Immunohistochemistry was performed to evaluate TS1 staining in tumours and in seven
human biopsies of primary SCLC from pulmonary bronchi. Central cell density and nucleus size were determined
in NCI-H69 sections.
Results: Twelve days after
177Lu-DOTA-Tyr
3-octerotate treatment, the SCLC xenograft response was extensive.
Twenty days after treatment, one of three analysed tumours displayed complete remission. The other two tumours
showed 1/4 the cell density of untreated controls and cell nuclei were about three times larger than those of
untreated controls. At 150 days after treatment, one of four mice exhibited complete remission. Treated tumours
displayed increased TS1 antibody accumulation and high TS1 binding in necrotic patches. All seven human SCLC
biopsies displayed necrotic areas with TS1 staining.
Conclusions: Radiation treatment with three injections of 30 MBq
177Lu-DOTA-Tyr
3-octreotate had pronounced
effects on tumour cell density and cell nuclei, which indicated mitotic catastrophe. Despite these anti-tumour
effects, two of three SCLC tumours recurred. Further studies should investigate the nature of tumour cell survival
and develop more effective treatments. High TS1 accumulation in tumour sections in vitro after
177Lu-DOTA-Tyr
3-
octerotate treatment indicated that TS1 might represent a promising secondary therapeutic strategy.
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Small-cell lung carcinoma (SCLC) comprises about 15-
20% of all diagnosed lung cancers. The prognosis of this
disease is often poor; distant metastases are typically
observed at the time of diagnosis. New improved treat-
ment modalities are urgently needed and have been
intensively discussed [1-3]. SCLC is characterised by
small- to medium- sized, tightly packed, highly mitotic
cells that generate prominent necrotic areas [4]. The ori-
gin of SCLC is neuroendocrine; the tumour cells express
neuroendocrine markers, somatostatin receptors, and
keratin 8, 18, and 19 [5-7]. In an effort to understand the
nature of these tumours, previous studies have investi-
gated the presence of cells with stem cell characteristics
[8-10], the consequences of the lack of wild-type p53
[11,12], and the over expression of Bcl-2 [13,14]. About
80-100% of all SCLC cells express somatostatin receptor
subtype 2 (SSTR2). Somatostatin receptor scintigraphy
can be used to visualise primary tumours and metastases
[15,16]. Radiolabelled somatostatin analogues have been
tested as a single therapy for SCLC, but this has not been
as promising as predicted, based on preclinical study
results [17-19]. However, the number of clinical studies
and the number of patients in those studies have been
relatively limited and the treatment protocol was not
optimised for those patients [20,21]. In contrast, patients
with gastro-entero-pancreatic tumours have been treated
successfully with somatostatin analogues [22,23]; further-
more, exogenous gene transfer of the SSTR2 gene into
SSTR-negative tumours has enabled treatment with
somatostatin analogues [24]. Previous animal studies
have shown that the somatostatin analogue, octreotate,
labelled with
177Lu (
177Lu-DOTA-Tyr
3-octreotate) might
be a promising treatment. Dosimetric studies revealed
that the therapeutic radionuclide,
177Lu, had physical
properties beneficial for therapy [25,26]. Because
177Lu
emits medium-energy electrons, it is suitable for treating
a wide range of tumour sizes. Its long physical half-life of
6.7 days and its higher retention in tumours compared to
normal tissues provides an optimal ratio of tumour to
normal tissue dose absorption. In a study by Schmitt
et al., nude mice that bore tumours of the human SCLC
cell line, NCI-H69, were used as a preclinical model. The
results demonstrated that single doses of 45-120 MBq
of
177Lu-DOTA-Tyr
3-octreotate caused extensive tumour
regression during the first 1-3 weeks after treatment [18].
In the same study, two 45-MBq fractions of
177Lu-DOTA-
Tyr
3-octreotate given 48 h apart caused more extensive
tumour regression. The tumours continued to decline
over the entire study period (34 days) [18]. However,
despite these promising results with fractionation proto-
cols, a later study by Kolby et al. demonstrated that the
SSTR2 receptors were saturated when doses above
30 MBq were given in one fraction [27]. Therefore, a
more frequent fractionation pattern with lower doses
might be more effective in a therapeutic setting. Another
study demonstrated that
177Lu-DOTA-Tyr
3-octreotate
treatment caused an up-regulation in somatostatin recep-
tor mRNA expression. That result supported the idea
that fractionated doses might induce receptor expression
and, consequently, increase the uptake of
177Lu-DOTA-
Tyr
3-octreotate [28,29]. However, new combinations of
therapies should be evaluated to achieve more effective
treatments for SCLC.
We hypothesised that somatostatin therapy combined
with an anti-keratin antibody might comprise an effec-
tive SCLC treatment. The
131I-radiolabelled monoclonal
antibody, thrombospondin-1 (TS1) [30], which binds
human keratin 8 (K8), has been successfully used in
experimental radiotherapy for HeLa cell tumours
[31,32]. K8 is a member of the intermediate filament
family, constitutes an important part of the cell cytoske-
leton, and is involved in many dynamic cellular pro-
cesses, like migration, invasion, and metastasis [33]. It
has also been demonstrated that the carboxyl-terminal
of K8 can function as a plasminogen receptor [34]. In
addition, some cell lines have highly tumourigenic
clones with increased expression of K8 [35]. The anti-
body TS1 binds with high affinity to a unique epitope in
K8 between amino acids 343 and 357; the abundance of
this epitope is very high in necrotic regions, due to the
low solubility of the K8 antigen and the high concentra-
tion of the antigen in tumour cells [36]. Because SCLC
tumours have extensive necrotic regions [4], radiola-
belled TS1 antibody accumulation could be sufficient
for effective radiation of the tumours. Targeted radio-
therapy with
177Lu-DOTA-Tyr
3-octreotate might further
increase the cytoplasmic release of K8 and thereby
increase the accumulation of radiolabelled TS1 antibo-
dies in SCLC tumours.
The main purpose of this study was to investigate the
binding of TS1 in small-cell lung cancer xenografts
after
177Lu-DOTA-Tyr
3-octreotate treatment. We ana-
lysed changes in tumour cell density, nuclear size, and
binding of TS1, Ki67, and Bcl-2 at different time points.
We also confirmed TS1 binding in a
177Lu-DOTA-Tyr
3-
octreotate-treated xenografts of the midgut carcinoid
cell line GOT1 and in tumour biopsies from seven
patients with small-cell carcinoma in pulmonary
bronchi.
Materials and methods
Animals and cell line
Four-week-old male BALB/c mice (Bommice; weight, 25 ±
0.5 g) underwent subcutaneous implantations in the neck
with 2 × 10
7 cells of the human SCLC cell line, NCI-H69
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Manassas, VA, USA) or the midgut carcinoid cell line
GOT1 [37]. Tumours were allowed to grow for 4 weeks to
a diameter of 10-15 mm. These experiments were
approved by the Ethical Committee for Animal Experi-
ments, University of Gothenburg. The animals were given
autoclaved food and drinking water ad libitum.T u m o u r
growth, animal condition, and body weight were deter-
mined at regular intervals. The animals were killed when
they lost > 10% of their original body weight or when the
tumour reached a diameter > 20 mm.
Patient material
This study included biopsies from seven cases of human
small-cell carcinoma in pulmonary bronchi that had not
been treated with radiolabelled somatostatin analogues.
Biopsies were fixed in formalin, embedded in paraffin,
and cut into 4-μm-thick sections. Sections from all seven
tumours were stained immunohistochemically with TS1
and sections from two tumours were analysed with anti-
SSTR2. The tissue material was decoded before proces-
sing to remove links that could identify patients.
Radiopharmaceuticals
DOTA-Tyr
3-octreotate (synthesised at the Institute of
Nuclear Medicine, University Hospital, Basel, Switzer-
land) was dissolved in a 0.05 M HCL solution that con-
tained 126 mg/ml sodium ascorbate and 25 mg/ml
gentisic acid (2,5-dihydroxybenzoic acid) [17,18].
177LuCl3 with 740 MBq/μg maximal specific activity
was obtained from Perkin Elmer (St. Louis, MO,
USA).
177LuCl3 was diluted to 4.2-5.3 MBq/μla n di n c u -
bated with the DOTA-Tyr
3-octreotate solution for
30 min at 80°C. This resulted in DOTA-Tyr
3-octreotate
with a specific activity of 30 MBq/μg. With instant thin
layer chromatography (ITLC-SG, Gelman, Ann Arbor,
MI, USA) performed as described previously [17,18], we
determined that > 98%
177Lu was bound to peptide.
Therapeutic study
Twenty SCLC-xenografted mice were injected in a lateral
tail vein with three fractions of 30 MBq
177Lu-DOTA-
Tyr
3-octreotate in 0.1-0.2 mL isotonic saline given 24 h
apart. One control group of the SCLC-xenografted mice
received no treatment (n = 5); the mice in this group
were killed after 20 days. The
177Lu-DOTA-Tyr
3-octreo-
tate-treated SCLC-xenografted mice were divided into
five groups that were sacrificed at 1 day (n = 5), 5 days
(n =5 ) ,1 2d a y s( n = 4), 20 days (n = 3), and 150 days
after treatment or until the tumour had regrown to the
original size (n = 4). The GOT1-xenografted mice were
divided into two groups untreated (n =3 )a n d3d a y s
(n = 3) of treatment. Tumour tissues were dissected,
fixed in buffered formalin for 4 to 24 h, and embedded in
paraffin. The tumours from each group were cut in serial
sections, 4 μm-thick, and subjected to haematoxylin/
eosin (H&E) staining, immunohistochemistry, and micro-
scopy to determine cell numbers (tumour and mouse
cells) and cell nucleus size.
Dosimetry
The dosimetry calculations were based on the pharmaco-
kinetics determined previously in NCI-H69 and GOT1
bearing nude mice [19,38]. In both tumours, instant
uptake was assumed; for NCI-H69 and GOT1, the instant
uptake rates were 5.8% IA/g and 14% IA/g, respectively.
For H69 tumours, activity concentrations were fit with a
declining monoexponential; the effective half-life was
determined to 5.8 days. We assumed that the emitted elec-
trons were totally absorbed in tumour tissues. We
neglected the small photon dose absorbed in tumours.
The different fractions were assumed to have similar bio-
kinetics, and the cumulative activity was determined by
integrating the monoexponential function up to the time
point of sacrifice. We determined the mean absorbed dose
by multiplying the cumulative activity by the emitted elec-
tron energy per decay; we expressed the results in gray
units. A similar calculation was used for the mean
absorbed dose in GOT1 tumours, except we could not use
a declining monoexponential fit, because the activity con-
centration increased during therapy [38]. Instead, we fit
the initial 7-day increase in concentration with a linear
model; then, we fit the concentration over the remaining
time with a declining monoexponential [38].
Antibodies for immunohistochemistry
Tumour sections from control mice (no treatment) and
from mice treated with
177Lu-DOTA-Tyr
3-octreotate were
stained with the following antibodies: monoclonal mouse
anti-human-Ki67 (Dako Glostrup, Denmark), monoclonal
mouse anti-human-Bcl-2 oncoprotein (Dako, Glostrup,
Denmark), monoclonal rabbit anti-somatostatin receptor
subtype 2 (anti-SSTR2), HPA007264 (Sigma-Aldrich
Corp., St. Louis, MO, USA), monoclonal mouse anti-
human wild type-p53 (Dako Glostrup, Denmark), mono-
clonal mouse anti-human CD133/1 (Miltenyi Biotec,
Bergisch Gladbach, Germany), monoclonal anti-human
thyroid transcription factor (TTF-1) (Dako Glostrup, Den-
mark), polyclonal anti-human synaptophysin (Dako
Glostrup, Denmark), and polyclonal anti-human chromo-
granin-A (Dako Glostrup, Denmark).
Hybridoma cell line that produced the monoclonal TS1
antibody, which reacted with keratin 8 (K8), was cultured
as described previously [39]. The TS1 antibody was puri-
fied from cell culture media with a Protein G column
(Amersham Pharmacia Biotech AB, Uppsala, Sweden)
and eluted with 0.1 M glycine/HCl buffer, pH 2.3. Frac-
tions were neutralised and stored at -20°C until use.
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H&E staining was performed on a few selected slides from
each group to study the morphology of the cells and deter-
mine the presence of necrosis, fibrosis, and apoptosis.
Necrosis was defined as an area stained with haematoxylin
that originated from proteins released from the cytoplasm
of dead cells. Fibrosis was defined as the presence of pro-
liferating fibroblast-like cells, often with an apoptotic
appearance. Apoptotic cells were defined as cells with
shrunken cytoplasms and nuclear chromatin condensation
or intense DNA staining in condensed pyknotic nuclei.
The epitope retrieval procedure for commercial antibo-
dies was performed as described by the manufacturer.
For TS1, we performed heat-induced epitope retrieval in
10 mM Tris/10 mM EDTA-buffer, pH 9.0. For immuno-
histochemical staining, we used 5 μg/ml TS1 and the
dilution recommended by the manufacturers for the
commercial antibodies. A minimum of one section from
t h r e et of i v et u m o u r sf r o me a c hg r o u pw a sa n a l y s e d
immunohistochemically with TS1, anti-Ki67, anti-Bcl-2.
Sections were also analysed with each antibody, as fol-
lows: anti-somatostatin receptor subtype 2 antibody, one
to three sections from each group; anti-human-p53, three
sections to confirm negativity; anti-human CD133/1, one
to two sections from each group; anti-human TTF-1,
three sections to confirm negativity; anti-synaptophysin,
five sections; and anti-chromogranin-A, five sections.
Appropriate positive controls were used for all antibo-
dies. The immunohistochemistry was performed with the
standard method of horseradish peroxidise and diamono-
benzidine (DAB) in a Dako autostainer with the EnVision
standard reagents. After the immunostaining, the nuclei
were counterstained with Mayer’s haematoxylin, dehy-
drated, and mounted.
Microscopic examination and calculation of the effect of
different treatment periods
To evaluate the overall effect of
177Lu-DOTA-Tyr
3-octreo-
tate in the SCLC xenograft, the ratio of tumour versus
mouse cells was calculated and the sizes of cell nuclei
were measured in a total of one to two sections from each
of two to five tumours in the different treatment groups.
A grid with 130 cross-points was placed over an area of
200 × 154 μm in the centre of each section. Tumour cells
were defined as cells that stained positively for Ki67 or
Bcl-2, cells with abnormal, angular, or polymorphic
morphologies, or cells with a hyperchromatic nucleus and
reduced cytoplasm. Those located within the cross-points
of the grid were counted. Normal mouse cells were
defined as cells that did not stain for Ki67 or Bcl-2 and
had morphologies of normal mouse fibroblasts, adipose,
and lymphoid cells.
In ten tumour cells, we measured the size of the
nucleus, or the area with nuclear chromatin, in the cells
in the centre of the section. We selected one to three
sections from two to four tumours of each group, and
systematically measured nuclei within the cross-points
of the 200 × 154 μm grid, starting at the top left corner
and continuing to the right bottom corner of the grid.
The nucleus diameter measurement was performed in
two directions and the value was expressed as the mean
value and standard deviation. We used a Zeiss AXIO
imager A1 microscope equipped with a Zeiss Axiocam.
The calculations for the positively and negatively stained
cells and for the nucleus size were confirmed with the
AXIO Vision programme, release 4.7 (data not shown).
Digital image analysis
The K8 and Ki67 expression levels in treated and
untreated NCI-H69 SCLC and GOT 1 midgut tumour
xenograft sections were quantified by analysing DAB
staining with the ImageJ programme developed by the
National Institute of Health [40]. The immunoRatio plu-
gin of the programme measured the DAB (brown) and
nuclei haematoxylin (blue) stains with an image resolu-
tion of 6.24 pixels/μm. Areas of 320 × 250 μmw e r ea n a -
lysed with the same light filter settings for each section.
The imaged areas with tumour cells were randomly cho-
sen, but areas of necrosis larger than 50 × 50 μma n d
mouse cells only were avoided. We analysed a total of
145 images from five, untreated SCLC tumour xenografts;
37 images from three, 1-day-treated, SCLC tumours;
74 images from four, 5-day-treated, SCLC tumours; 75
images from three, 12-day-treated, SCLC tumours;
33 images from two, 20-day-treated, SCLC tumours; and
57 images from three, regrown SCLC tumours. For the
GOT 1 tumour xenografts, we analysed 63 images from
three, untreated tumours and 83 images from four, 3-
day-treated tumours. Between 10 and 40 sections from
each group of SCLC and GOT1 xenografts were stained
with Ki67 and similarly analysed. The mean percentages
and standard deviations were calculated for K8 and
Ki67 DAB stains. The results were compared with two-
sided Students t tests and the significance level was set at
P <0 . 0 5 .
Within each of the seven biopsies, two to nine 320 ×
250 μm areas with tumour cells, necrotic tissue, and
high TS1 staining were captured at a ×40 magnification
and a resolution of 6.24 pixels/μm. These images were
analysed with ImageJ plugin ImmunoRatio to calculate
the percentage of DAB staining.
Results
Dosimetry
The injection of three times 30 MBq resulted in differ-
ent mean absorbed doses to the H69 tumour tissue. For
the mice sacrificed 1, 5, 12, 20, or 150 days after last
injection the mean absorbed dose was estimated to be
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Page 4 of 1313, 32, 51, 59, and 64 Gy, respectively. The mean
absorbed dose to the GOT1 tumours was estimated to
be 27 Gy.
Haematoxylin/eosin staining
Histologically, the untreated control, 1-day-treated and
regrown tumours showed the classical SCLC cell mor-
phology with abnormal, angular, polymorphic, hyper-
chromatic nuclei, and scant cytoplasm. Large necrotic
regions were present in the untreated, 1- and 5-day-trea-
ted tumours. After 12 and 20 days of treatment, the lar-
ger necrotic regions were replaced by fibrotic tissue to a
large extent. H&E staining showed that the control
tumours and regrown tumours were similar, but the
regrown tumours had slightly larger areas of fibrosis.
Compared to the untreated controls, treated tumours,
particularly after 5 days, had higher numbers of small (50
×5 0μm) necrotic regions. Relatively few cells exhibited
an apoptotic appearance with a shrunken cytoplasm and
intensely stained DNA in condensed pyknotic nuclei. In
tumours treated for 5 days, a slightly higher number of
apoptotic cells with intense hematoxylin staining were
observed between the necrotic areas and viable cells.
Immunohistochemistry
The tumour cells from the xenograft of the human SCLC
cell line NCI-H69 and the human cell line GOT1 stained
positively with specific binding for TS1, anti-Ki67, and
anti-Bcl-2. An increase in the intensity of the TS1, anti-
Ki67, and anti-Bcl-2 staining per cell was also observed
in tumour cells treated with
177Lu-DOTA-Tyr
3-octreotate
(Figures 1, 2, 3, and 4).
All tumour cells in the SCLC xenograft were negative
for the anti-CD-133/1, and as expected negative for anti-
p53 and anti-TTF-1. The sections of the xenograft also
stained positively, with some unspecific binding, for anti-
SSTR2, anti-synaptophysin, and anti-chromogranin-A.
TS1 exhibited a distinct cytoplasmic pattern of staining
in viable tumour cells, but also demonstrated binding to
necrotic regions and pyknotic/apoptotic tumour cells
(Figure 1). The staining of necrotic regions was high in
both large and small areas, with some variation in stain-
ing intensity (Figure 1). The percentage of DAB staining
(mean value and standard deviation) in each tumour was
calculated with imageJ ImmunoRatio and presented in
Table 1. Despite high variation in staining intensities
between different tumours within the same group a sig-
nificant increase could be seen between the untreated
group and the 5- and 12-days-treated groups. Untreated
SCLC NCI-H69 tumours showed 13% K8 expression, and
this increased significantly to 44% after 5 days (p < 0.05;
n = 4) and 38% after 12 days (p < 0.05; n = 3). After 20
days of treatment, the mean value in the two analysed
tumours was 40% (Figure 2a). In GOT1 xenografts,
Figure 1
177Lu-DOTA-Tyr
3-octreotate treatment effects on tumour cells visualised by staining with the anti-K8 antibody, TS1.( A)U n t r e a t e d ,
midgut GOT1 xenograft; (B) Midgut GOT1 xenograft after 3 days of treatment; small necrotic areas are evident. (C) Untreated, SCLC NCI-H69 xenograft
with viable, apoptotic, and necrotic cells; (D) SCLC NCI-H69 xenograft after 1 day of treatment; (E) SCLC NCI-H69 xenograft after 5 days of treatment;
small necrotic areas are evident; and (F) SCLC NCI-H69 xenograft after 12 days of treatment. Red arrows indicate small necrotic areas, blue arrows point
to apoptotic cells, and white or black arrows point to cells with multiple nuclei and micronuclei. Scale bar 100 μm.
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increased significantly to 58% after 3 days of treatment
(p < 0.05; n = 3; Figure 2b).
Ki67, a marker for proliferation, is present in the
nucleus in all active phases of the cell cycle, but absent
in resting G0 cells. Cells with classical SCLC cell mor-
phology in the untreated, one, five and regrown tumours
exhibited 70-90% Ki67 staining, and after 12 and 20
days, the staining was reduced to 45% and 25% respec-
tively (Figure 2). The Ki67 staining in the midgut cell
line that was about 20% in the untreated tumour and
was reduced to 10% in the 3-day-treated tumours (Fig-
ure 2a,b). Sections were interpreted as tumour cell nega-
tive when cells lacked the SCLC cell morphology and
stained negative for Ki67 (Figure 3).
Bcl-2 is an integral membrane protein expressed in the
endoplasmic reticulum (ER), the outer membranes of
mitochondria, and in the nuclear envelope. In this study,
Bcl-2 expression was located in the tumour cell cyto-
plasm (ER and/or mitochondria) of untreated tumours.
During treatment with
177Lu-DOTA-Tyr
3-octreotate, the
Bcl-2 staining gradually localised to the tumour cell
nuclei, and in regrown tumours, it reappeared in the
cytoplasm (Figure 4).
Effect of treatment with
177Lu-DOTA-Tyr
3-octreotate
The histological examination demonstrated that
177Lu-
DOTA-Tyr
3-octreotate had a dramatic effect on the
tumour cells. After only 12 days of treatment, a 50%
reduction in tumour cell density was observed in three of
four tumours, and the fourth tumour showed only a few
viable tumour cells at the edge of the tumour (Figure 5).
After 20 days of treatment, the tumour cell density was
further reduced, and in one section, all cells were Ki67
negative and displayed no SCLC cell morphology (inter-
preted as no detectable tumour cells; Figure 3).
The treatment also caused an increase in the average size
of the cell nucleus (Figure 1, 3, 4, and 6). After 20 days of
treatment, the average nucleus size was nearly three times
larger than that of untreated controls. Several of the
tumour cells were multinucleated, and some had character-
istic micronuclei, where a nuclear membrane surrounded
chromosomal material close to, but outside the large
nucleus (Figure 1). This multinuclear and/or micronuclear
appearance increased with time after treatment.
As mentioned above, histological results showed that
the xenograft tumours stained positive for anti-SSTR2
with some unspecific binding. No increase in SSTR2
positivity could be observed in tumour xenograft sec-
tions at any time after treatment with
177Lu-DOTA-
Tyr
3-octreotate.
Untreated controls and regrown tumours were similar
in TS1, anti-Ki67, and anti-Bcl-2 staining. They also
showed similar cell numbers and nuclear sizes.
Serial sections of specimens from seven humans with
primary bronchial small-cell carcinoma were also studied
with the TS1 and anti-SSTR2 antibodies. In one of the
two cases analysed with both antibodies (case 1; Figure 7),
we observed similar binding patterns for TS1 and anti-
SSTR2. In the other case (case 2; Figure 7), the staining for
SSTR2 was more intense. The biopsies had approximately
Figure 2 Radiation effects on TS1 and Ki67 DAB-positive
immunostaining.( a) Radiation effects on TS1 and Ki67 DAB-
positive immunostaining in the SCLC NCI-H69 xenograft. The X-axis
shows the numbers of days treated with
177Lu-DOTA-Tyr
3-octreotate.
The Y-axis shows the percentage (%) mean value and standard
deviation of DAB-positive immunostaining for TS1 and Ki67. Bars
that are close together represent results from different sections of
the same tumour group. TS1 (black bars), Ki67 (white bars). The 5-
and 12-days treatment differ significantly from the untreated, p <
0.05, 5-days n = 4 and 12-days n =3 .( b) Radiation effects on TS1
and Ki67 DAB-positive immunostaining in the midgut GOT1
xenograft. The X-axis shows the numbers of days treated with
177Lu-
DOTA-Tyr
3-octreotate. The Y-axis shows the percentage (%) mean
value and standard deviation of DAB-positive immunostaining for
TS1 and Ki67. Bars that are close together represent results from
different sections of the same tumour group. TS1 (black bars), Ki67
(white bars). Three-days treatment differ significantly from the
untreated, p < 0.05, n =4 .
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2, but the number of areas with
tumour cells, necrotic tissue, and high TS1 staining varied.
Between two to nine 320 × 250-μm areas with tumour
cells, necrotic tissue, and high TS1 binding per case were
analysed with ImageJ ImmunoRatio to determine the DAB
staining after TS1 immunohistochemistry (Table 2). Ima-
geJ ImmunoRatio results from three cases, with low, med-
ium, and high staining, are presented in Figure 8.
Discussion
Our results showed that treatment with three fractions
of 30 MBq
177Lu-DOTA-Tyr
3-octreotate given in 24-h
intervals had pronounced effects. The activity per frac-
tion was restricted to 30 MBq per injection, because
higher amounts had demonstrated saturation [27]. How-
ever, the cumulative activity was 90 MBq, which was
equal to that measured in our previous study with two
treatments of 45 MBq [18]. This new fractionation pro-
tocol appeared to be more effective, although this
observation was not statistically significant, probably due
to the limited number of animals included in both
studies.
The goal in this study was to achieve a high tumour
response and to analyse the histological changes that
occurred during therapy. Our focus was on K8 expres-
sion during therapy. To strengthen the claim of treat-
ment efficacy based on observed increases in K8
expression during therapy, we included mice xeno-
grafted with the human midgut carcinoid cell line,
GOT1.
For the SCLC cell line H69 tumours, the three times 30
MBq protocol caused minor effects after 1 day, somewhat
more pronounced after 5 days, and extensive after 12 and
20 days. After 12 days, we observed a nearly 100% regres-
sion (cell number) in one of four tumours (n = 4); in the
other three specimens, the cell number had reduced to
about 50% of that observed in the untreated control.
After 20 days of treatment, tumour cells were eliminated
Figure 3 Histological sections of treated and untreated SCLC tumours labelled with Ki67.( A, B) Different magnifications of the same
tumour after 20 days of treatment; (C) a Ki67-negative tumour after 20 days of treatment; (D) a representative untreated tumour labelled with
Ki67.
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tumours, the cell density had reduced to one fourth of
that observed in the untreated control. It is well known
that irradiation of tumour cells can induce several cell-
death mechanisms, including apoptosis, necrosis, autop-
hagy, senescence, and mitotic catastrophe [41]. A striking
histological finding was the enlarged nuclei observed in
sections from tumours at 20 days after
177Lu-DOTA-
Tyr
3-octreotate treatment. These nuclei had enlarged to
about three times the size of the nuclei in the untreated
control. This enlargement was sometimes accompanied
by the appearance of multinucleated cells. The formation
of multinucleated giant cells was most likely a result of
mitotic loss or mitotic catastrophe in the cells.
It has previously been demonstrated that the expres-
sion of SSTR2 mRNA was upregulated as a result
of
177Lu-DOTA-Tyr
3-octreotate treatment. This sug-
gested that fractionated
177Lu-DOTA-Tyr
3-octreotate
treatment could provide the optimal effect [25,26]. The
human and mouse SSTR2 proteins are 98% homologous;
thus, it is likely that the monoclonal rabbit anti-SSTR2
antibody used in this study could bind to both human
and mouse SSTR2. We observed no increase in SSTR2
staining in the tumour xenograft after treatment.
Human and mice have different DNA sequences in the
coding regions of the SSTR2 gene. According to BLAST
alignments, the Homo sapiens somatostatin receptor 2
(NM 001050.2) has 88% identity with the Mus musculus
somatostatin receptor 2 (NM 009217.3). However, the
mRNA levels of a gene do not always correlate to the
levels of protein expression. Thus, PCR-based methods
may provide more accurate information on the expres-
sion of mouse and human SSTR2 mRNA in this type of
xenograft system.
By visual examination, the positivity of TS1, anti-Ki67,
and anti-Bcl-2 appeared to increase in the remaining
viable cells of the treated tumours (Figure 1, 3, and 4).
There are two subtypes of keratins, the relatively acidic,
Figure 4 Histological sections of treated SCLC tumours labelled with Bcl-2.( A) A tumour after 5 days of treatment; (B) a tumour after 12
days of treatment; (C) a tumour after 20 days of treatment; Bcl-2 localisation is mainly in the nuclei; (D) a representative tumour that regrow
after treatment; Bcl-2 localisation is mainly cytoplasmic.
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Page 8 of 13type I, and the basic, type II, the different types can form
complexes in a 1:1 molar ratio a process that leads to the
formation of 10-nm-thick filaments [6,33]. In the SCLC
cell line H69, the type I keratins 18 (K18), form com-
plexes with K8 of type II. The increase in TS1 binding
may have been due to the irradiation of the cells, which
may have induced apoptotic caspase-cleavage of K18 and
subsequently an increased exposure of the keratin 8 epi-
tope [42]. However, relatively few apoptotic cells were
observed in the sections. Alternatively, non-apoptotic
mechanisms that induced phosphorylation or other mod-
ifications of keratin 8, which subsequently rearranged the
cytoskeleton, may have led to increased exposure of the
TS1-related keratin 8 epitope [43]. The histological sec-
tions also showed that Bcl-2 accumulated in the nuclei
after radiation exposure (Figure 4). It was previously
demonstrated that Bcl-2 could inhibit apoptosis and also
inhibit multiple DNA-repair pathways; thus, tumour cells
Table 1 Level of TS1 staining in the SCLC NCI-H69 and
GOT1 midgut xenografts
Tumour Treatment Images Mean
value
Standard
deviation
1 Untreated SCLC 29 27.8 15.3
2 19 8.3 6.2
3 33 8.5 6.2
4 23 11.5 6.3
5 41 12.0 7.8
6 1-day SCLC 17 39.0 7.4
7 6 10.8 4.4
8 14 25.8 6.7
9 5-day SCLC 20 60.8 5.7
10 19 62.4 9.8
11 18 27.7 4.6
12 17 24.4 6.1
13 12-day SCLC 40 58.1 10.0
14 13 20.4 3.0
15 22 36.2 9.8
16 20-day SCLC 17 41.4 17.9
17 16 39.4 15.7
18 Regrown SCLC 18 20.3 13.0
19 15 40.7 10.3
20 24 4.2 2.5
21 Untreated
midgut
18 40.3 10.5
22 13 42.7 14.1
23 32 17.6 15.3
24 3-day midgut 21 49.3 10.7
25 35 60.8 10.6
26 14 52.7 17.3
27 13 60.7 9.5
The table illustrates the number of images analysed, mean value, and
standard deviation per analysed tumour. The percentage (%) DAB-positive
immunostaining for TS1 in the tumour xenografts was determined by use of
ImageJ ImmunoRatio.
Figure 5 Radiation effects on densities of mouse and tumour
cells. The X-axis shows the numbers of days of
177Lu-DOTA-Tyr
3-
octreotate treatment. The numbers of mouse and tumour cells were
determined for a defined reference area in the centre of the tumour.
Bars that are close together represent results from different sections
of the same tumour. The numbers of tumour and mouse cells
represent different tumours for the untreated group (n = 2), the 1-
day-treatment group (n = 2), the 5-day-treatment group (n = 5), the
12-day-treatment group (n = 4), the 20-day-treatment group (n = 3),
and the 150-day-treatment or regrown tumours group (n = 3).
Figure 6 Radiation effects on tumour cell nuclear diameters.
The X-axis shows the numbers of days of treatment. The nuclear
diameters were measured in a defined reference area in the centre
of the tumour; one to three sections were measured in two to four
tumours from each group. Bars that are close together represent
results from different sections of the same tumour. The nuclei were
measured in different tumours for the untreated group (n = 2), the
1-day-treatment group (n = 2), the 5-day-treatment group (n = 4),
the 12-day-treatment group (n = 4), and the group with regrown
tumour cells (n = 2).
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Page 9 of 13exposed to DNA-damaging substances, like nitrosamine,
exhibited an accumulation of Bcl-2 in the nuclei [44].
The high expression of Ki67 and Bcl-2 in combination
with the non-functional p53 could have contributed to
cell tumourigenicity, regrowth of tumour cells, and the
formation of radiation-damaged multinucleated giant
cells with improper chromosome segregation and cell
division behaviours [41,45,46]. The majority of these
giant cells had probably divided a few times to become
polyploidy/multinucleated cells that eventually died by
delayed apoptosis or necrosis [47,48]. However, some
theories have suggested that these cells may survive
Figure 7 Serial sections of primary tumours from humans with small-cell carcinoma in pulmonary bronchi.( A, B) representative serial
sections from patient 1; (C, D) representative serial sections from patient 2. (A) and (C) show sections labelled with the anti-K8 antibody, TS1; (B)
and (D) show sections labelled with an anti-SSTR2 antibody.
Table 2 Level of TS1 staining in selected regions of primary bronchial small-cell carcinoma biopsies
Case Image 1 Image 2 Image 3 Image 4 Image 5 Image 6 Image 7 Image 8 Image 9
1 17.9 45.2 44.1 12.3 8.6 41.8 31.6 - -
2 44.9 19.0 16.1 - -----
3 8 . 0 5 . 5 -------
4 4 . 7 5 . 1 -------
5 31.0 22.9 430 32.9 68.7 58.9 71.0 60.8 49.5
6 9.9 15.7 3.3 4.4 -----
7 81.7
a 11.6 9.0 11.2 13.1 14.4 - - -
The biopsies had approximately the same size 10-20 mm
2 but the number of areas with tumour cells and necrotic tissue varied. Between two to nine 320 × 250-
μm areas with tumour cells, necrotic tissue, and high TS1 binding per case were analysed. The percentage (%) DAB-positive immunostaining for TS1 in seven
cases of primary bronchial small-cell carcinomas was determined by use of ImageJ ImmunoRatio.
aContains many intact tumour cells.
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Page 10 of 13t h r o u g har e v e r s ep o l y p l o i d yp a t h w a yt h a tm a yb ea c t i -
vated by the self-renewal stem cell genes, NANOG,
OCT4, and SOX2 [49]. Despite the extensive effects
of
177Lu-DOTA-Tyr
3-octreotate treatment observed after
12 and 20 days, only one of four tumours showed 100%
regression after 150 days; the recurrent tumours were
histologically similar to untreated tumours. This sug-
gested that, in the majority of tumours, a few cells must
have escaped radiation treatment and regained tumour
cell properties and viability. Resistance to treatment,
relapse, and the presence of metastases has been attribu-
ted to the presence of resting cancer stem cells. Other
studies have identified cells with the stem cell marker,
CD-133, in SCLC tumours [8]. However, we did not find
any CD-133 positive cells in sections from the H69 SCLC
xenografts.
Viable tumour cells could be detected within in the
outermost regions of large necrotic areas in untreated
(Figure 1C), 1- and 5-day-treated tumours as well as
regrown tumours. It is important to reach and kill these
few viable cells that have escaped the previous treatment.
However, resting viable tumour cells within necrotic
areas are usually difficult to reach with immuno-targeting
agents not only due to the lack of blood supply but also
because of absent or low antigen concentration. The bio-
chemical properties of K8, including low solubility, high
stability, and intracellular expression, differ from those of
membrane-bound target antigens. If the target antigen is
present in very high concentrations close to the tumour
cells, like K8 in these necrotic regions, targeting is
expected to be more successful compared to a mem-
brane-bound antigen. To our knowledge, targeting
exposed intracellular tumour antigens is a unique
approach. Currently, TS1 is the only antibody that has
been shown, in experimental studies, to kill tumour cells
by targeting an intracellular antigen exposed in necrotic
tissue [30,31,50,51].
We detected an increased exposure of the TS1 target,
K8 in particular in small necrotic areas in tumours after
5a n d3d a y so f
177Lu-DOTA-Tyr
3-octreotate treatment
in both the NCI-H69 SCLC and midgut GOT1 xeno-
grafts. The optimal time point to administrate TS1
should be when the level of smaller necrotic regions is
high. In vivo diffusion capability of TS1 have been
demonstrated earlier [30,31,50,51] and these small areas
of necrotic tissue created by
177Lu-DOTA-Tyr
3-octreo-
tate treatment as well as the outermost areas of larger
necrotic regions can probably be reached by diffusion of
the TS1 antibody over short distances in vivo.
High affinity interaction between an antibody and its
antigen not only enables a longer antibody retention in
tumours it can also reduce the distance an antibody will
Figure 8 ImageJ ImmunoRatio result from the analysis of the primary bronchial small-cell carcinomas. One case with low staining (case
4, left), one case with medium staining (case 1, middle) and one case with high staining (case 5, right).
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Page 11 of 13diffuse within a tumour, therefore comparison of intact
and fragments of TS1 should be studied in the future.
Recently, monovalent and divalent scFv forms of TS1
were generated that had better diffusion capabilities
[52]. It was also demonstrated that a combination of the
TS1-binding, anti-idiotypic antibody, aTS1, in complex
with TS1 provided improved tumour penetration in
HeLa HEp-2 multicellular tumour spheroids and experi-
mental tumours [51].
In the human biopsies of primary bronchial small-cell
carcinoma, tumour cells showed high positivity for
SSTR2 and normal cells tended to be negative. In con-
trast, these biopsies showed positivity for TS1 in normal
lung epithelial cells, tumour cells, and in necrotic regions
between fast growing viable tumour cells. In vivo,o n e
would not expect TS1 to target intact viable normal cells
or tumour cells. However, necrotic regions present in the
biopsies were generally small, and close to fast dividing
tumour cells. These facts might facilitate contact between
TS1 and K8 and increase the distribution of TS1 close to
viable tumour cells in vivo. Image analysis of the biopsies
demonstrated that five out of seven patient biopsies in
the analysed regions expressed K8 to an equal or higher
level than that observed in untreated SCLC xenografts. In
addition, a pre-radiation treatment with
177Lu-DOTA-
Tyr
3-octreotate would most likely further increase the
level of exposed K8 in the tumour.
Conclusions
There is an urgent need for new improved treatment
modalities for SCLC. The results presented in this study
are relevant to the understanding of potential pathways
for development within this field. Our results on the
tumour xenografts suggested that
177Lu-DOTA-Tyr
3-
octreotate, when administered in optimised, fractionated
doses in combination with other treatments, could be
an alternative treatment also for SCLC.
Our results demonstrated that
177Lu-DOTA-Tyr
3-
octreotate treatment increased the TS1 accumulation in
vitro in SCLC and midgut xenografts. This indicated that
the combination of
177Lu-DOTA-Tyr
3-octreotate and radi-
olabelled TS1 could be valuable to investigated further
since it holds promise as a future treatment for SCLC.
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